Dr. Lena-Sophie Schütter
Investment Manager
About me
| Team | Life Sciences & Chemistry |
| at HTGF since | 2024 |
CV
Dr. Lena Schütter is an Investment Manager in the Life Science Team at HTGF in Bonn. Prior to this, she worked for several years in various sales positions at QIAGEN GmbH. She completed her studies in molecular biology in Göttingen. During her studies, she completed numerous internships in Germany and abroad. Lena Schütter then completed her doctorate in genetics at the renowned ageing research institute CECAD in Cologne. In addition to her doctorate, Lena Schütter studied business administration at the University of Hagen.
My success stories in the HTGF portfolio
Mevaldi is a biochemical company and a pioneer in the field of bio-based building blocks for sustainable polymers, polyesters, and polyurethanes. Since 2020, the company has been developing 3MPD: an …
to Mevaldi
MDA was founded in 2023 by Dr Gunter Trojandt, Annett Christ and two business angels, Jozsef Bugovics and Nils Kröber. MDA has a total of 10 employees and is based …
to Medical Decision Alliance
inContAlert was founded in September 2022 within the ecosystem of the University of Bayreuth. The MedTech startup’s sensor system empowers patients with neurogenic bladder dysfunction to manage their bladder on …
to inContAlert
Altavo is a Dresden based medical technology startup founded in February 2021. Based on non-invasive radar sensing and AI algorithms for speech recognition and synthesis, Altavo is developing prosthetics to …
to Altavo
NAVAN, Inc. (NAVAN) is an early-stage private biotechnology company developing a novel, proprietary NanoStraw platform to enable the next generation of cell and gene therapies. A non-viral physical delivery technology, …
to Navan
Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in …
to Signatope
Guided to exit
Exit
GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with …
to GQ Bio Therapeutics
Recent posts
Zum Artikel
Biotech company Mevaldi successfully closes funding round with HTGF and ICIG Ventures to scale up breakthrough technology for green chemistry
Zum Artikel
Social Media & contact
LinkedIn
Dr. Lena-Sophie Schütter
Profil